Clinical Trial of Gemcitabine and Oxaliplatin in Recurrent or Metastatic Breast Cancer
Status:
Terminated
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out if the combination of gemcitabine and oxaliplatin
chemotherapy will be effective in reducing or eliminating the tumor(s) in patients with
recurrent or metastatic breast cancer.
Gemcitabine is a chemotherapy drug approved by the U.S. Food and Drug Administration (FDA)
for the treatment of pancreatic and lung cancer; oxaliplatin is a chemotherapy drug that is
approved by the FDA for the treatment of colon cancer. Neither gemcitabine nor oxaliplatin
are approved for the treatment of breast cancer. However, both drugs have been shown to
decrease the size of breast cancer tumors.